Spots Global Cancer Trial Database for acalabrutinib
Every month we try and update this database with for acalabrutinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) | NCT02537444 | Ovarian Cancer | Acalabrutinib acalabrutinib a... | 18 Years - | Acerta Pharma BV | |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | NCT04716075 | Chronic Lymphoc... Chronic Graft-v... Mantle Cell Lym... Adverse Event Response Rate | Acalabrutinib 2... | 18 Years - 80 Years | Polish Lymphoma Research Group | |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT06428019 | Chronic Lymphoc... | Venetoclax Acalabrutinib Obinutuzumab | 18 Years - | AbbVie | |
| ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | NCT02029443 | Chronic Lymphoc... Small Lymphocyt... Richter's Syndr... Prolymphocytic ... | Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | NCT04402138 | Mantle Cell Lym... | Acalabrutinib | 18 Years - | SCRI Development Innovations, LLC | |
| A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas | NCT04548648 | Central Nervous... | Acalabrutinib Isavuconazole | 18 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | NCT04505254 | Chronic Lymphoc... Small Lymphocyt... | Acalabrutinib Obinutuzumab | 18 Years - | M.D. Anderson Cancer Center | |
| Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease | NCT04198922 | Recurrent Moder... Hematopoietic a... | Acalabrutinib Questionnaire A... | 18 Years - | Fred Hutchinson Cancer Center | |
| A Study Of The Selective PKC-β Inhibitor MS- 553 | NCT03492125 | Chronic Lymphoc... Small Lymphocyt... Aggressive Lymp... | MS-553 MS-553 acalabrutinib venetoclax Rituximab obinutuzumab | 18 Years - | MingSight Pharmaceuticals, Inc | |
| Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma | NCT05820841 | Large B-cell Ly... Diffuse Large B... | R-miniCHOP + Ac... R-miniCHOP | 61 Years - | Universität des Saarlandes | |
| AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer | NCT04630756 | Advanced Haemat... | AZD4573 Acalabrutinib | 18 Years - 130 Years | AstraZeneca | |
| Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | NCT05256641 | Diffuse Large B... High-grade B-ce... Transformed Lym... Secondary Centr... | Acalabrutinib | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | NCT05197192 | Chronic Lymphoc... | Obinutuzumab Venetoclax Acalabrutinib | 18 Years - 120 Years | German CLL Study Group | |
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. | NCT05205252 | Relapsed Hemato... Refractory Hema... | Tazemetostat Tafasitamab Lenalidomide Acalabrutinib Daratumumab (In... Mosunetuzumab Daratumumab (Su... Hyaluronidase-F... Pomalidomide Dexamethasone 2... | 18 Years - | Ipsen | |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | NCT06136559 | Chronic Lymphoc... Small Lymphocyt... | Nemtabrutinib Ibrutinib Acalabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Acalabrutinib Real World Italian obSErvational Study -ARISE | NCT06205498 | Chronic Lymphoc... | acalabrutinib | 18 Years - | AstraZeneca | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Retention Rate of Acalabrutinib in a Non-interventional Setting | NCT05645172 | Chronic Lymphoc... | 18 Years - 99 Years | AstraZeneca | ||
| A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | NCT04529772 | Diffuse Large B... | acalabrutinib placebo Prednisone Rituximab Cyclophosphamid... Vincristine Doxorubicin | 18 Years - 75 Years | Acerta Pharma BV | |
| A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | NCT02972840 | Lymphoma, Mantl... | Acalabrutinib Bendamustine Rituximab Placebo | 65 Years - | Acerta Pharma BV | |
| Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | NCT04626791 | Mantle Cell Lym... | Acalabrutinib Bortezomib Cyclophosphamid... Cytarabine Doxorubicin Hyd... Prednisone Rituximab Rituximab and H... | 18 Years - 75 Years | Academic and Community Cancer Research United | |
| Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies | NCT03932331 | Phase I: Relaps... Phase II Cohort... Phase II Cohort... | Acalabrutinib | 18 Years - 130 Years | AstraZeneca | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | NCT04783415 | Mantle Cell Lym... | Acalabrutinib Ublituximab Umbralisib | 18 Years - | City of Hope Medical Center | |
| Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma | NCT02180711 | Non Hodgkin Lym... | acalabrutinib rituximab (IV) Lenalidomide | 18 Years - | Acerta Pharma BV | |
| A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies | NCT03198650 | Part1: Advanced... Part2: r/rCLL a... Part3: Untreate... | Acalabrutinib Obinutuzumab | 20 Years - 120 Years | AstraZeneca | |
| Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | NCT03946878 | Blastoid Varian... CCND1 Protein O... CD20 Positive CD5 Positive FCER2 Negative Pleomorphic Var... Recurrent Mantl... Refractory Mant... t(11;14)(q13;q3... | Acalabrutinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | NCT04883437 | Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Indolent Non-Ho... Lymphoplasmacyt... Lymphoprolifera... Mantle Cell Lym... Marginal Zone L... | Acalabrutinib Obinutuzumab Quality-of-Life... Questionnaire A... | 18 Years - | Emory University | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors | NCT06211413 | Chronic Lymphoc... Atrial Fibrilla... Hypertension Cardiotoxicity | no intervention | 22 Years - | Abramson Cancer Center at Penn Medicine | |
| Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. | NCT04604067 | Diffuse Large B... | Acalabrutinib | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | NCT05065554 | IgM MGUS Waldenstrom Mac... Neuropathy;Peri... | Acalabrutinib Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT05057494 | Chronic Lymphoc... | Acalabrutinib Venetoclax Obinutuzumab | 18 Years - 130 Years | AstraZeneca | |
| Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) | NCT02537444 | Ovarian Cancer | Acalabrutinib acalabrutinib a... | 18 Years - | Acerta Pharma BV | |
| PICAROS - Acalabrutinib RWE on 1L CLL in Spain | NCT05999877 | Chronic Lymphoc... | 18 Years - | AstraZeneca | ||
| Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease | NCT04198922 | Recurrent Moder... Hematopoietic a... | Acalabrutinib Questionnaire A... | 18 Years - | Fred Hutchinson Cancer Center | |
| Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | NCT03836261 | Chronic Lymphoc... | Acalabrutinib Venetoclax Chemoimmunother... Obinutuzumab | 18 Years - 130 Years | Acerta Pharma BV | |
| Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | NCT04505254 | Chronic Lymphoc... Small Lymphocyt... | Acalabrutinib Obinutuzumab | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | NCT04016805 | Chronic Lymphoc... | Ublituximab Umbralisib Ibrutinib Venetoclax Acalabrutinib O... | 18 Years - | TG Therapeutics, Inc. | |
| Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | NCT02296918 | Chronic Lymphoc... Small Lymphocyt... Prolymphocytic ... | acalabrutinib Obinutuzumab Venetoclax Rituximab | - | Acerta Pharma BV | |
| A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma | NCT05951959 | Mantle Cell Lym... | Acalabrutinib Venetoclax Rituximab | 18 Years - | AstraZeneca | |
| A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | NCT05197192 | Chronic Lymphoc... | Obinutuzumab Venetoclax Acalabrutinib | 18 Years - 120 Years | German CLL Study Group | |
| Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | NCT04402138 | Mantle Cell Lym... | Acalabrutinib | 18 Years - | SCRI Development Innovations, LLC | |
| HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I) | NCT03685708 | Hepatitis Safety and Tole... | HEPLISAV-B | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | NCT06054776 | Mantle Cell Lym... | Acalabrutinib Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Echocardiograph... Glofitamab Multigated Acqu... Obinutuzumab Positron Emissi... | 18 Years - | City of Hope Medical Center | |
| Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL | NCT04560322 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Obinutuzumab Acalabrutinib | 18 Years - | Massachusetts General Hospital | |
| Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | NCT02112526 | Activated B-cel... | Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | NCT03863184 | Mantle Cell Lym... | Acalabrutinib Lenalidomide Rituximab | 18 Years - | Weill Medical College of Cornell University | |
| Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia | NCT05336812 | Chronic Lymphoc... Small Lymphocyt... | Acalabrutinib Obinutuzumab Venetoclax | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | NCT04257578 | B-Cell Non-Hodg... Diffuse Large B... High Grade B-Ce... Primary Mediast... Transformed Fol... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... | Acalabrutinib Axicabtagene Ci... | 18 Years - | University of Washington | |
| Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma | NCT04404088 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Grade 3a Follic... | Acalabrutinib Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL | NCT05952024 | Diffuse Large B... | Acalabrutinib Rituximab | 65 Years - 99 Years | AstraZeneca | |
| Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | NCT03623373 | Mantle Cell Lym... | Bendamustine Rituximab Acalabrutinib Cytarabine Leukapheresis Peripheral bloo... Oral rinse Bone marrow col... | 18 Years - 70 Years | Washington University School of Medicine | |
| Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | NCT04189952 | Diffuse Large B... Chronic Lymphoc... Small Lymphocyt... Marginal Zone L... | Acalabrutinib Rituximab Ifosfamide Carboplatin Etoposide | 18 Years - | University of Miami | |
| A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | NCT04529772 | Diffuse Large B... | acalabrutinib placebo Prednisone Rituximab Cyclophosphamid... Vincristine Doxorubicin | 18 Years - 75 Years | Acerta Pharma BV | |
| Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT04169737 | Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... | Acalabrutinib Obinutuzumab Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia | NCT04075292 | Untreated Chron... | Acalabrutinib Rituximab Chlorambucil | 18 Years - 130 Years | AstraZeneca | |
| Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | NCT04462328 | Primary Central... | Durvalumab Acalabrutinib | 18 Years - | Washington University School of Medicine | |
| HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I) | NCT03685708 | Hepatitis Safety and Tole... | HEPLISAV-B | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL | NCT04560322 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Obinutuzumab Acalabrutinib | 18 Years - | Massachusetts General Hospital | |
| Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients | NCT04008706 | Chronic Lymphoc... | Acalabrutinib | 18 Years - 130 Years | AstraZeneca | |
| Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT05388006 | Chronic Lymphoc... Richter Syndrom... Small Lymphocyt... | Acalabrutinib Durvalumab Venetoclax | 18 Years - | Mayo Clinic | |
| Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL | NCT04883749 | Chronic Lymphoi... | Acalabrutinib | 18 Years - | German CLL Study Group | |
| Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. | NCT04604067 | Diffuse Large B... | Acalabrutinib | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | NCT04002947 | Non-Hodgkin's L... Diffuse Large B... DLBCL NHL | DA-EPOCH Rituximab CHOP Acalabrutinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia | NCT04075292 | Untreated Chron... | Acalabrutinib Rituximab Chlorambucil | 18 Years - 130 Years | AstraZeneca | |
| Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma | NCT04189757 | Mantle Cell Lym... | Acalabrutinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT03328273 | Chronic Lymphoc... | Ceralasertib Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | NCT04765111 | Mantle Cell Lym... | Acalabrutinib Rituximab | 65 Years - | M.D. Anderson Cancer Center | |
| Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma | NCT05820841 | Large B-cell Ly... Diffuse Large B... | R-miniCHOP + Ac... R-miniCHOP | 61 Years - | Universität des Saarlandes | |
| ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | NCT02029443 | Chronic Lymphoc... Small Lymphocyt... Richter's Syndr... Prolymphocytic ... | Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | NCT02972840 | Lymphoma, Mantl... | Acalabrutinib Bendamustine Rituximab Placebo | 65 Years - | Acerta Pharma BV | |
| A Study Of The Selective PKC-β Inhibitor MS- 553 | NCT03492125 | Chronic Lymphoc... Small Lymphocyt... Aggressive Lymp... | MS-553 MS-553 acalabrutinib venetoclax Rituximab obinutuzumab | 18 Years - | MingSight Pharmaceuticals, Inc | |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT06428019 | Chronic Lymphoc... | Venetoclax Acalabrutinib Obinutuzumab | 18 Years - | AbbVie | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer | NCT02570711 | Metastatic Panc... | ACP-196 Nab-paclitaxel Gemcitabine | 18 Years - | Acerta Pharma BV | |
| Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | NCT02296918 | Chronic Lymphoc... Small Lymphocyt... Prolymphocytic ... | acalabrutinib Obinutuzumab Venetoclax Rituximab | - | Acerta Pharma BV | |
| Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL | NCT04685915 | Chronic Lymphoc... | Ibrutinib Copanlisib Acalabrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| Acalabrutinib in CNSL | NCT04906902 | Central Nervous... Refractory Cent... Recurrent Centr... | Acalabrutinib | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
